Indivior Pharmaceuticals Inc Ordinary Share Financials

Utili: I risultati di Q3 2026 sono stati pubblicati in data gio ott 29th, prima dell'apertura del mercato

Fusioni e acquisizioni: Indivior Pharmaceuticals (INDV) was merged with Supernus Pharmaceuticals (SUPN) on Monday, November 2, 2026

Indivior Pharmaceuticals Inc Ordinary Share Financials

Indivior Pharmaceuticals Inc Ordinary Share (INDV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Indivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.295B-$1.365B vs $1.334B Est

Indivior Pharmaceuticals (NASDAQ:INDV) affirms FY2026 sales outlook from $1.295 billion-$1.365 billion to $1.295 billion-$1.365 billion vs $1.334 billion estimate.

Benzinga Newsdesk

PRO
Indivior Q3 Adj. EPS $1.32 Beats $1.12 Estimate, Sales $356.000M Beat $329.350M Estimate

Indivior (NASDAQ:INDV) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.12 by 17.86 percent. This is a 83.33 percent increase over earnings of $0.72 per share from the same

Benzinga Newsdesk

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.215 billion-$1.285 billion to $1.295 billion-$1.365 billion vs $1.245 billion estimate.

Benzinga Newsdesk

PRO
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.125 billion-$1.195 billion to $1.215 billion-$1.285 billion vs $1.156 billion estimate.

Benzinga Newsdesk

Indivior Pharmaceuticals Inc Ordinary Share

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Indivior Pharmaceuticals Inc Ordinary Share Financials

Earnings & Guidance News

PRO
Indivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.295B-$1.365B vs $1.334B Est

PRO
Indivior Q3 Adj. EPS $1.32 Beats $1.12 Estimate, Sales $356.000M Beat $329.350M Estimate

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est

PRO
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate

Earnings Scheduled For April 30, 2026

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est

Indivior Pharmaceuticals Inc Ordinary Share

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Indivior Pharmaceuticals Inc Ordinary Share Financials

Earnings & Guidance News

PROIndivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.295B-$1.365B vs $1.334B Est

PROIndivior Q3 Adj. EPS $1.32 Beats $1.12 Estimate, Sales $356.000M Beat $329.350M Estimate

PROIndivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est

PROIndivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate

Earnings Scheduled For April 30, 2026

PROIndivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est

PRO
Indivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.295B-$1.365B vs $1.334B Est

PRO
Indivior Q3 Adj. EPS $1.32 Beats $1.12 Estimate, Sales $356.000M Beat $329.350M Estimate

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est

PRO
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est